350 related articles for article (PubMed ID: 31340854)
1. Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association.
Tonsing-Carter E; Hernandez KM; Kim CR; Harkless RV; Oh A; Bowie KR; West-Szymanski DC; Betancourt-Ponce MA; Green BD; Lastra RR; Fleming GF; Chandarlapaty S; Conzen SD
Breast Cancer Res; 2019 Jul; 21(1):82. PubMed ID: 31340854
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.
West DC; Kocherginsky M; Tonsing-Carter EY; Dolcen DN; Hosfield DJ; Lastra RR; Sinnwell JP; Thompson KJ; Bowie KR; Harkless RV; Skor MN; Pierce CF; Styke SC; Kim CR; de Wet L; Greene GL; Boughey JC; Goetz MP; Kalari KR; Wang L; Fleming GF; Györffy B; Conzen SD
Clin Cancer Res; 2018 Jul; 24(14):3433-3446. PubMed ID: 29636357
[No Abstract] [Full Text] [Related]
3. GR and ER Coactivation Alters the Expression of Differentiation Genes and Associates with Improved ER+ Breast Cancer Outcome.
West DC; Pan D; Tonsing-Carter EY; Hernandez KM; Pierce CF; Styke SC; Bowie KR; Garcia TI; Kocherginsky M; Conzen SD
Mol Cancer Res; 2016 Aug; 14(8):707-19. PubMed ID: 27141101
[TBL] [Abstract][Full Text] [Related]
4. Interaction of glucocorticoid receptor (GR) with estrogen receptor (ER) α and activator protein 1 (AP1) in dexamethasone-mediated interference of ERα activity.
Karmakar S; Jin Y; Nagaich AK
J Biol Chem; 2013 Aug; 288(33):24020-34. PubMed ID: 23814048
[TBL] [Abstract][Full Text] [Related]
5. Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth.
Kach J; Long TM; Selman P; Tonsing-Carter EY; Bacalao MA; Lastra RR; de Wet L; Comiskey S; Gillard M; VanOpstall C; West DC; Chan WC; Griend DV; Conzen SD; Szmulewitz RZ
Mol Cancer Ther; 2017 Aug; 16(8):1680-1692. PubMed ID: 28428441
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression.
Kinyamu HK; Archer TK
Mol Cell Biol; 2003 Aug; 23(16):5867-81. PubMed ID: 12897156
[TBL] [Abstract][Full Text] [Related]
7. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
8. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
[TBL] [Abstract][Full Text] [Related]
9. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer.
Pan D; Kocherginsky M; Conzen SD
Cancer Res; 2011 Oct; 71(20):6360-70. PubMed ID: 21868756
[TBL] [Abstract][Full Text] [Related]
10. Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis.
Zou Y; Tsai WB; Cheng CJ; Hsu C; Chung YM; Li PC; Lin SH; Hu MC
Breast Cancer Res; 2008; 10(1):R21. PubMed ID: 18312651
[TBL] [Abstract][Full Text] [Related]
11. Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer.
Prekovic S; Schuurman K; Mayayo-Peralta I; Manjón AG; Buijs M; Yavuz S; Wellenstein MD; Barrera A; Monkhorst K; Huber A; Morris B; Lieftink C; Chalkiadakis T; Alkan F; Silva J; Győrffy B; Hoekman L; van den Broek B; Teunissen H; Debets DO; Severson T; Jonkers J; Reddy T; de Visser KE; Faller W; Beijersbergen R; Altelaar M; de Wit E; Medema R; Zwart W
Nat Commun; 2021 Jul; 12(1):4360. PubMed ID: 34272384
[TBL] [Abstract][Full Text] [Related]
12. The glucocorticoid receptor interferes with progesterone receptor-dependent genomic regulation in breast cancer cells.
Ogara MF; Rodríguez-Seguí SA; Marini M; Nacht AS; Stortz M; Levi V; Presman DM; Vicent GP; Pecci A
Nucleic Acids Res; 2019 Nov; 47(20):10645-10661. PubMed ID: 31598691
[TBL] [Abstract][Full Text] [Related]
13. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer.
Eeckhoute J; Carroll JS; Geistlinger TR; Torres-Arzayus MI; Brown M
Genes Dev; 2006 Sep; 20(18):2513-26. PubMed ID: 16980581
[TBL] [Abstract][Full Text] [Related]
14. Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.
Prekovic S; Chalkiadakis T; Roest M; Roden D; Lutz C; Schuurman K; Opdam M; Hoekman L; Abbott N; Tesselaar T; Wajahat M; Dwyer AR; Mayayo-Peralta I; Gomez G; Altelaar M; Beijersbergen R; Győrffy B; Young L; Linn S; Jonkers J; Tilley W; Hickey T; Vareslija D; Swarbrick A; Zwart W
EMBO Mol Med; 2023 Dec; 15(12):e17737. PubMed ID: 37902007
[TBL] [Abstract][Full Text] [Related]
15. Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition.
Kinyamu HK; Collins JB; Grissom SF; Hebbar PB; Archer TK
Mol Carcinog; 2008 Nov; 47(11):845-85. PubMed ID: 18381591
[TBL] [Abstract][Full Text] [Related]
16. The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells.
Wang C; Mayer JA; Mazumdar A; Brown PH
Breast Cancer Res Treat; 2012 Jun; 133(2):487-500. PubMed ID: 21947652
[TBL] [Abstract][Full Text] [Related]
17. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
[TBL] [Abstract][Full Text] [Related]
18. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
Marsaud V; Gougelet A; Maillard S; Renoir JM
Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
[TBL] [Abstract][Full Text] [Related]
19. miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.
Tian X; Zhang Z
IUBMB Life; 2018 Jan; 70(1):71-80. PubMed ID: 29247596
[TBL] [Abstract][Full Text] [Related]
20. Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells.
Lazennec G; Katzenellenbogen BS
Mol Cell Endocrinol; 1999 Mar; 149(1-2):93-105. PubMed ID: 10375022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
